Hey there! Welcome!
Get updated on
Key Trials
Casirivimab and Imdevimab Antibody Cocktail Clinically Beneficial in High Risk COVID-19 Patients
Casirivimab and Imdevimab antibody cocktail resulted in lesser requirement of mechanical ventilation and high-flow oxygen with no deaths as compared to the controls in symptomatic Covid-19 patients. The non-vaccinated patients who received this antibody cocktail did not require mechanical ventilation and those who were fully immunized seldom entailed high-flow oxygen. Casirivimab and Imdevimab treatment regimen is clinically beneficial for high risk COVID19 patients.


Med Dialogues 2023
Conference Highlights
Patient education


A wide range of informative monographs, booklets and newsletters; all developed in-house by Cipla.

View all

Our Research

Snapshots of clinical research on molecules and diseases conducted by Cipla.

View all